腹腔热灌注化疗在卵巢恶性肿瘤术后中的应用

目的探讨和观察腹腔热灌注化疗在卵巢恶性肿瘤术后的应用及临床疗效。方法将符合条件的60例患者随机分为两组。治疗组35例，为顺铂腹腔热灌注联合紫杉醇静脉双径路化疗；对照组25例，为单行TP方案静脉化疗。观察两组CA125下降，腹水控制率及不良反应。结果两组术后的CA125水平无明显差异（P〉0．05）。热灌注后治疗组平均CA125值降至23．5U／ml，对照组平均CA125值降至56．7U／ml，差异有统计学意义（P〈0．05）。两组的腹水控制率（CR＋PR）分别为80％和52％，差异具有统计学意义（P〈0．05）。两组的不良反应差异有统计学意义（P〈0．05）。结论采用顺铂腹腔热灌注联合静脉化疗治疗卵巢癌的疗效优于单纯静脉化疗，且不良反应小，值得临床推广应用。

Application of intraperitoneal hyperthermal chemotherapy for malignant ovarian neoplasm after surgery

Objective To explore the application and efficacy of intraperitoneal hyperthermal chemotherapy in the treat- ment of malignant ovarian neoplasm after surgery. Methods Sixty patients with ovarian carcinoma were selected and randomrized into two groups. There were 35 cases in the treatment group, receving the intraperitoneal hyperthermal chemotherapy with DDP and intravenous chemotherapy with FFX, and 25 cases in the contrast group, receiving intrave- nous chemotherapy with PTX and DDP. The serum CA 125 ,the ascites control rate and the main side effects were ob- served in the two groups. Results There was no significant differences in CA125 level in the two groups（P 〉 0. 05）. The mean level of CA125 in the treatment group fall to 23.5 U/m1 after aperitoneal hyperthermic chemotherapy,while in the contrast group,it was 56. 7 U/ml（P 〈 0. 05 ）. The ascites control rate was 80% in the treatment group and 52% in the contrast group,with a significant difference between the two groups（P 〈 0. 05）. There was a significant difference in the rates of the main side effects in the two groups （P 〈 0. 05）. Conclusion The efficacy of intraperitoneal hyperthermal chemotherapy combined with intravenous chemotherapy is preferable to intravenous chemotherapy alone in the treatment of advanced malignant ovarian neoplasm with less side effects.